Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Type I procollagen synthesis pathway
- Molecular classification
- Other
01
Overview
Type I procollagen is synthesized as prepro-α chains (two α1 and one α2 encoded by COL1A1/COL1A2) on the rough ER, signal peptides are removed to form pro-α chains, which undergo hydroxylation of proline and lysine (vitamin C–dependent), glycosylation of hydroxylysine, triple-helix assembly, and ER quality control assisted by the collagen-specific chaperone Hsp47; procollagen is secreted, its N- and C-terminal propeptides are cleaved extracellularly to yield mature type I collagen that polymerizes into fibrils, while the released propeptides (PINP, PICP) enter the circulation and serve as biomarkers of synthesis.
- Other names
- Procollagen type I biosynthesisCollagen type I biosynthesisType I collagen maturation/processing
02
Mechanism of action
Ascorbic acid enables proline and lysine hydroxylation in procollagen via prolyl 4-hydroxylase and lysyl hydroxylase, stabilizing the triple helix and permitting proper secretion and fibrillogenesis Modulating ER chaperone Hsp47 could, in principle, alter procollagen folding/quality control (research context)
03
Biological functions
Extracellular matrix assemblyTissue tensile strength and structural integrityBone matrix formation and remodelingWound healing and skin recoveryProtein quality control in the endoplasmic reticulum (ER)
04
Disease associations
Fibrosis (pathologic excess type I collagen)Osteogenesis imperfecta and Ehlers–Danlos syndromes (defects in collagen I synthesis/quality)Bone disorders/osteoporosis monitoring (via synthesis biomarkers)Skin aging and scarring (altered collagen I turnover)
05
Safety considerations
Targeting the global synthesis pathway risks broad effects on connective tissues (bone, skin, tendon), potentially causing fragility, poor wound healing, or impaired bone qualityInhibition could provoke ER stress or misfolded protein responses due to disrupted procollagen quality control
06
Interacting drugs
Ascorbic acid (vitamin C; essential cofactor for hydroxylation steps)
1 more in the full profile.
07
Biomarkers
Procollagen type I C-terminal propeptide (PICP) in serum reflects the rate of type I collagen synthesis and is used to monitor bone formation and skin recovery; PICP is released stoichiometrically with collagen I formation and is more stable in serum than PINP in some contextsProcollagen type I N-terminal propeptide (PINP) is also used clinically for bone formation monitoring, though it can be less stable than PICP depending on assay/fragment measured
Beyond the preview
Go deeper on Type I procollagen synthesis pathway.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Type I procollagen synthesis pathway.